Guru Ownership Trend
Guru Analysis for Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. (ZNTL), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q4 2025, a total of 4 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $8.06 M.
Top institutional holders include Renaissance Technologies (RenTech) and Steven Cohen.
Institutional sentiment is currently Bullish. This is evidenced by a $806,909.38 net inflow during the quarter.
Recent activity highlights Steven Cohen who opened a new position. Conversely, Cliff Asness reduced exposure by 57.0%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q4 2025)
Guru Consensus (Q4 2025)
FAQs for Zentalis Pharmaceuticals, Inc. (ZNTL)
Major holders include Renaissance Technologies (RenTech) ($3.89 M), Steven Cohen ($135,392), Cliff Asness ($62,093). According to the latest reported data, 4 tracked investment managers collectively hold approximately 3.06 M shares.
According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $806,909.38, with 2 managers increasing positions and 1 managers reducing holdings.
During the most recent reporting period, 1 managers trimmed their positions, while 0 fully exited ZNTL. The total reported sell value was $82,309.17.
Yes, 1 managers opened new positions in ZNTL, and 1 increased their existing holdings. The total reported buy value was $889,218.55.